New lupus drug shows promise in routine care

NCT ID NCT07424261

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Feb 20, 2026 · Last updated May 23, 2026 · Updated 15 times

Summary

This study is tracking 125 adults with lupus who are starting a new drug called anifrolumab. The goal is to see how well the drug controls disease activity and helps patients achieve remission over two years. Researchers are collecting data from regular doctor visits and patient questionnaires to understand the drug's real-world effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Altenburg, Germany
Research Site
RECRUITING

Bad Bramstedt, Germany
Research Site
RECRUITING

Berlin, Germany
Research Site
RECRUITING

Chemnitz, Germany
Research Site
RECRUITING

Erlangen, Germany
Research Site
RECRUITING

Heidelberg, Germany
Research Site
RECRUITING

Herne, Germany
Research Site
RECRUITING

Kassel, Germany
Research Site
RECRUITING

Leipzig, Germany
Research Site
RECRUITING

Meerbusch-Lank, Germany
Research Site
RECRUITING

München, Germany
Research Site
RECRUITING

Planegg, Germany
Research Site
RECRUITING

Schwerin, Germany
Research Site
RECRUITING

Trier, Germany
Research Site
RECRUITING

Wetzlar, Germany
Research Site
RECRUITING

Wuppertal, Germany

Conditions

Explore the condition pages connected to this study.

LUPUS ERYTHEMATOSUS, SYSTEMIC